Atara Biotherapeutics, Inc.

NASDAQ:ATRA

Biotechnology

Healthcare
$6.77 +1.96%

+$0.19 today

Market cap
$68.98M
Beta
0.11
P/E (TTM)
-14.7
EPS (TTM)
-$0.67
52W Low $3.92High $19.15

Volume 0.02M

Average 1.40M

ATRA Common Stock Issued

Cash raised by issuing new shares.

Atara Biotherapeutics, Inc.NASDAQ: ATRA

Common Stock Issued · Q1 FY2026 · quarter ended Mar 2026

Common stock issued outflow grows to $2.95M

Q1 FY2026 common stock issued was $2.95M, compared with $0 a year earlier. Trailing-twelve-month common stock issued was $19.29M. Over 3 fiscal years it compounded at -9.3% a year.

Context

  • Common stock issued amounted to 13.5% of revenue in FY2025, down 33.0 pp from a year earlier.
  • Common stock issued increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly common stock issued holds near $2.95M or moves back toward the trailing-twelve-month quarterly average of $4.82M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.95M+98466.7% QoQ
Last fiscal yearDec 2025
$16.35M-72.7% YoY
LTMMar 2026
$19.29M-45.8% YoY
Common Stock Issued past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-72.7%——
3-year CAGR-9.3%——
5-year CAGR——
10-year CAGR——

Common Stock Issued history

USD · from the cash flow

Latest · FY2025
16.35M USD
Year-over-year change
-72.7%
4-year CAGR
-36.2%

Common Stock Issued vs competitors

How ATRA compares with its peers on the latest reported figures

  • Peers report in different currencies, so common stock issued is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -45.8% is the 7th highest of 10, against a peer median of -6.0%.
  • Common stock issued amounts to 83.4% of revenue for ATRA, versus a peer median of 1189.7%.
ATRA Competitors
Common Stock Issued for ATRA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OVIDOvid Therapeutics Inc.LTM Mar 2026$164.18M USD+40238.1%+646.7%2305.2%
STROSutro Biopharma, Inc.LTM Mar 2026$103.37M USD+5.6%-81.2%103.8%
COYACoya Therapeutics, Inc.LTM Mar 2026$31.36M USD+114.2%+4950.0%395.1%
STTKShattuck Labs, Inc.LTM Mar 2026$26.22M USD+2495.6%+538.3%2621.6%
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026$19.29M USD-45.8%-9.3%83.4%
IFRXInflaRx N.V.LTM Mar 2026€16.2M EUR-6.0%+139.7%55236.8%
CLNNClene Inc.LTM Mar 2026$2.66M USD-77.7%-3.2%1984.3%
CSBRChampions Oncology, Inc.LTM Jan 2026$240K USD-23.8%+15.6%0.4%
MGNXMacroGenics, Inc.LTM Mar 2026$140K USD-82.4%-50.8%0.1%
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$0 USD———
CNTXContext Therapeutics Inc.LTM Mar 2026$0 USD-100.0%-46.9%—
Peer median (excluding ATRA) —-6.0%+15.6%1189.7%

Competitors are the stored peer set for ATRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(340.14M)(228.3M)(276.13M)(85.4M)32.69M
Depreciation & Amortization9.35M5.65M4.83M5.05M2.38M
Deferred Income Tax1.79M0000
Stock-Based Compensation53.87M53.84M45.39M27M9.75M
Change in Working Capital52.58M(61.47M)15.34M(30.96M)(104.74M)
Accounts Receivables264K(39.24M)6.11M32.63M229K
Inventory3.34M(1.59M)(8.12M)(4.43M)10.66M
Accounts Payables9.07M(9.21M)(3.13M)687K(4.24M)
Other Working Capital39.91M(11.44M)20.48M(59.84M)(111.38M)
Other Non-Cash Items2.04M(40.15M)17.59M15.59M8.98M
Operating Cash Flow(220.52M)(270.43M)(192.98M)(68.72M)(50.94M)
Capital Expenditures(10.58M)(4.19M)(1.22M)(246K)0
Acquisitions (Net)(32.84M)000948K
Purchases of Investments(301.13M)(180.59M)(83.65M)(19.67M)(7.89M)
Sales of Investments333.97M292.97M208.71M28.54M25.09M
Other Investing Activities32.84M94.77M25K00
Investing Cash Flow22.26M202.96M123.87M8.62M18.15M
Debt Repayment(254K)(518K)(947K)(892K)(250K)
Common Stock Issued98.7M21.89M2.14M59.95M16.35M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities5.5M31.71M821K223K(1K)
Financing Cash Flow103.94M53.08M2.01M59.28M16.1M
Effect of Forex Changes00000
Net Change in Cash(94.32M)(14.39M)(67.1M)(811K)(16.69M)
Free Cash Flow(231.1M)(274.62M)(194.2M)(68.96M)(50.94M)

Atara Biotherapeutics, Inc.

NASDAQ:ATRA

Intrinsic Alpha fair value

Locked

Current Price

$6.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.